Invasive Aspergillosis Clinical Trial
Official title:
Prospective, Observational Study of the Role of Primary Antifungal Prophylaxis to Prevent Invasive Aspergillosis in Elderly Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy
In previous retrospective study (SEIFEM 2016 study) the investigators evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of mold active primary antifungal prophylaxis (PAP) in a "real life" setting of acute myeloid leukemia (AML )patients receiving intensive consolidation therapy. All cases of proven/probable IA, observed during consolidation chemotherapy in adult and pediatric AML patients between 2011 and 2015, were retrospectively collected in a multicenter study involving 38 Italian hematologic centers. The investigators observed 56 (2.2%) cases of IA [43 probable (1.7%) and 13 proven (0.5%)]. The overall mortality rate and the mortality rate attributable to IA (AMR) on day 120 were 16% and 9%, respectively. In multivariate analysis, parameters that influenced the outcome were age ≥60 years and treatment with high doses of cytarabine (HDAC). The investigators also observed that centers involved in this survey had different antifungal policies during the AML consolidation phase. The results from this study show that in a large real-world setting the mold active PAP, with itraconazole or posaconazole, decreases the rate of IA after consolidation course. In SEIFEM 2016 study the investigators demonstrated that the incidence of IA during the AML consolidation is low. However, the mortality is not negligible, mainly in older patients. Further, a sub-analysis in the subset of patients older than 60 years demonstrated that patients who didn't receive mold active prophylaxis had higher incidence of IA than patients who received mold active prophylaxis (15% vs 6%). Therefore, as prophylaxis seems to prevent IA in consolidation, further studies should be performed especially in elderly patients treated with HDAC to confirm our data and to identify the subset of patients who require PAP.
Evaluate the protective role of mold active PAP in patients older than 60 years underwent to chemotherapy of consolidation with intermediate or high doses of cytarabine ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06028451 -
ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
|
||
| Completed |
NCT00163722 -
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients
|
Phase 3 | |
| Completed |
NCT02394483 -
Single Ascending Oral Dose Study of F901318
|
Phase 1 | |
| Completed |
NCT01128907 -
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
|
N/A | |
| Completed |
NCT00404092 -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
|
Phase 2 | |
| Recruiting |
NCT01386437 -
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
|
||
| Withdrawn |
NCT02912026 -
Radiolabelled IV and Oral Metabolism Study of F901318
|
Phase 1 | |
| Withdrawn |
NCT03076905 -
Pharmacokinetics of IV Formulation
|
Phase 1 | |
| Withdrawn |
NCT03095547 -
Drug/Drug Interactions With F901318
|
Phase 1 | |
| Completed |
NCT02737371 -
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT00836875 -
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
|
Phase 3 | |
| Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
| Terminated |
NCT04876716 -
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
|
Phase 3 | |
| Recruiting |
NCT05101187 -
Olorofim Aspergillus Infection Study
|
Phase 3 | |
| Enrolling by invitation |
NCT02104479 -
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
|
||
| Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
| Terminated |
NCT02396225 -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
|
N/A | |
| Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
| Completed |
NCT00334412 -
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
|
Phase 4 | |
| Completed |
NCT04550936 -
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
|